Benzinga · Aug 10, 2026
Claritev Analysts Raise Their Forecasts Following Q2 Earnings
CTEV reported better-than-expected Q2 results and raised FY26 sales guidance. Analysts maintain Buy ratings with increased price targets.
CT
NYSE · CTEV
Claritev Corporation
Healthcare · Medical - Healthcare Information Services
$35.32
Up+$1.94 (+5.49%)
Updated Aug 13, 2026, 3:49 PM
SID Score
6.8/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 641.19M
- P/E ratio
- -1.87
- Dividend yield
- 0.00%
- 52-week range
- $11.50 – $38.99
- Volume
- 125.66K
- Avg. volume
- 180.27K
Price performance
CTEV price history
1M range · 21 trading sessions · Daily adjusted prices
CTEV closed at $35.32 after 21 trading sessions, up 19.97% for the selected period.
- Last close
- $35.32
- Period change
- +19.97%
- Period low
- $21.61
- Period high
- $35.32
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 12, 2026 | $35.75 | $36.14 | $34.6541 | $35.32 | 125.66K |
| Aug 11, 2026 | $34.48 | $35.43 | $33.275 | $34.96 | 140.57K |
| Aug 10, 2026 | $33.25 | $36.39 | $32.03 | $34.07 | 151.23K |
| Aug 7, 2026 | $29.135 | $38.99 | $29.135 | $32.59 | 330.24K |
| Aug 6, 2026 | $25.91 | $27.2925 | $25.16 | $26.84 | 80.7K |
| Aug 5, 2026 | $26.08 | $27.02 | $25.27 | $26.13 | 63.92K |
| Aug 4, 2026 | $25.08 | $27.00 | $24.67 | $26.40 | 68.13K |
| Aug 3, 2026 | $22.91 | $24.83 | $22.91 | $24.29 | 55.92K |
| Jul 31, 2026 | $23.93 | $24.55 | $22.65 | $22.71 | 72.85K |
| Jul 30, 2026 | $24.17 | $24.17 | $22.24 | $23.58 | 71.35K |
| Jul 29, 2026 | $22.34 | $24.18 | $22.34 | $23.40 | 73.2K |
| Jul 28, 2026 | $21.97 | $23.36 | $21.16 | $22.67 | 75.71K |
| Jul 27, 2026 | $21.73 | $22.65 | $21.73 | $21.82 | 81.92K |
| Jul 24, 2026 | $23.55 | $24.00 | $21.45 | $21.61 | 69.05K |
| Jul 23, 2026 | $24.23 | $24.9882 | $22.6375 | $23.27 | 122.05K |
| Jul 22, 2026 | $27.55 | $27.85 | $24.755 | $24.98 | 128.65K |
| Jul 21, 2026 | $30.30 | $30.71 | $28.61 | $28.69 | 65.08K |
| Jul 20, 2026 | $30.41 | $30.595 | $29.16 | $30.12 | 244.97K |
| Jul 17, 2026 | $30.41 | $31.2278 | $29.63 | $30.39 | 73.65K |
| Jul 16, 2026 | $29.87 | $31.53 | $28.27 | $30.76 | 120.42K |
| Jul 15, 2026 | $27.93 | $30.14 | $27.93 | $29.44 | 101.6K |
Latest CTEV news
The latest Smart Investors Daily articles mentioning CTEV.
Stock researchCompany · Overview
CTEV research
Overview
Company profile and research snapshot.
Company profile
Claritev Corp is a healthcare technology, data, and insights company focused on improving transparency, affordability, and quality. The company provides tech-enabled solutions and services to interpret clients' needs and customize solutions that combine its payment integrity, network-based, and analytics-based services. The Company's focus is being a value-added provider of data analytics and technology-enabled end-to-end cost management, payment, and revenue integrity solutions to the U.S. healthcare industry.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- —
- Implied upside
- —
- Analysts
- 9
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 12, 2026 | Wells Fargo | Equal-Weight | — |
| Aug 10, 2026 | Citigroup | Buy | — |
| Aug 10, 2026 | Canaccord Genuity | Buy | — |
| Jul 21, 2026 | Canaccord Genuity | Buy | — |
| May 29, 2026 | Canaccord Genuity | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 10, 2026
Citigroup Maintains Buy on Claritev, Raises Price Target to $45
Citigroup analyst Daniel Grosslight maintains Claritev (NYSE:CTEV) with a Buy and raises the price target from $40 to $45.
Benzinga · Aug 10, 2026
Canaccord Genuity Maintains Buy on Claritev, Raises Price Target to $43
Canaccord Genuity analyst Richard Close maintains Claritev (NYSE:CTEV) with a Buy and raises the price target from $37 to $43.
Yahoo · Aug 8, 2026
Claritev Q2 Earnings Call Highlights
Claritev (NYSE:CTEV) reported second-quarter revenue growth, record bookings and higher cash flow, prompting the healthcare technology company to raise its full-year revenue, adjusted EBITDA and free-cash-flow outlook. Revenue totaled $257.5 million in the second quarter, up 6.6% from a year earlie
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
